Amlodipine-Valsartan Combination Decreases Central Systolic Blood Pressure More Effectively Than the Amlodipine-Atenolol Combination The EXPLOR Study

被引:171
作者
Boutouyrie, Pierre [1 ]
Achouba, Assya [2 ]
Trunet, Patrick [2 ]
Laurent, Stephane
机构
[1] Univ Paris 05, Hop Europeen Georges Pompidou, Assistance Publ Hop Paris, Dept Pharmacol,INSERM,U970,Team 7, F-75015 Paris, France
[2] Novartis Pharmaceut, Paris, France
关键词
hypertension; blood pressure; aorta; arteries; antihypertensive agents; compliance; randomized; controlled trial; ARTERY FUNCTION EVALUATION; CENTRAL AORTIC PRESSURE; LOCAL PULSE PRESSURE; ANTIHYPERTENSIVE TREATMENT; WAVE REFLECTION; HEART-RATE; ESSENTIAL-HYPERTENSION; CONSENSUS DOCUMENT; RANDOMIZED-TRIAL; BETA-BLOCKERS;
D O I
10.1161/HYPERTENSIONAHA.109.148999
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
The beta-blocker atenolol is less effective than angiotensin-receptor blockers and calcium-channel blockers for reducing central blood pressure (BP). The trial was designed to determine whether the advantages of angiotensin-receptor blockers over atenolol remained significant when both were combined with the calcium-channel blocker amlodipine. A prospective, randomized, blinded endpoint (PROBE design) parallel group, multicenter trial including 393 patients with essential hypertension resistant to 4 weeks of 5 mg of amlodipine was set out. Central systolic BP, augmentation index (AIx; either rough or adjusted on heart rate), and carotid-to-femoral pulse wave velocity were measured with applanation tonometry (SphygmoCor) at inclusion and after 8 and 24 weeks of active treatment with an amlodipine-valsartan combination (5/80 mg and then 10/160 mg) or an amlodipine-atenolol combination (5/50 mg and then 10/100 mg). From baseline to week 24, central systolic BP decreased significantly more in the amlodipine-valsartan group (-13.70 +/- 1.15 mm Hg; P<0.0001) than in the amlodipine-atenolol group (-9.70 +/- 1.10 mm Hg; P<0.0001; difference: -4.00 mm Hg [95% CI: -7.10 to -0.90]; P=0.013), despite similar changes in brachial systolic BP. The difference in rough AIx reduction was -6.5% (95% CI: -8.3 to -4.7; P<0.0001) in favor of amlodipine-valsartan. AIx adjusted on heart rate was significantly reduced in favor of amlodipine-valsartan (-2.8% [95% CI: -4.92 to -0.68]; P<0.01). Heart rate decreased significantly more with amlodipine-atenolol ( difference: -11 bpm [95% CI: -14 to -8 bpm]; P<0.001). Pulse wave velocity decreased by 0.95 m/s in both groups with no significant difference. Differences in central systolic BP and rough AIx remained significant after adjustment to the changes in heart rate. The amlodipine-valsartan combination decreased central (systolic and pulse) pressure and AIx more than the amlodipine-atenolol combination. (Hypertension. 2010;55:1314-1322.)
引用
收藏
页码:1314 / U54
页数:15
相关论文
共 35 条
[1]   Central blood pressure measurements and antihypertensive therapy a consensus document [J].
Agabiti-Rosei, Enrico ;
Mancia, Giuseppe ;
O'Rourke, Michael F. ;
Roman, Mary J. ;
Safar, Michel E. ;
Smulyan, Harold ;
Wang, Ji-Guang ;
Wilkinson, Ian B. ;
Williams, Bryan ;
Vlachopoulos, Charalambos .
HYPERTENSION, 2007, 50 (01) :154-160
[2]   Effects of antihypertensive treatment on small artery remodelling [J].
Agabiti-Rosei, Enrico ;
Heagerty, Anthony M. ;
Rizzoni, Damiano .
JOURNAL OF HYPERTENSION, 2009, 27 (06) :1107-1114
[3]   Heart rate, arterial stiffness, and wave reflections in paced patients [J].
Albaladejo, P ;
Copie, X ;
Boutouyrie, P ;
Laloux, BE ;
Déclère, AD ;
Smulyan, H ;
Bénétos, A .
HYPERTENSION, 2001, 38 (04) :949-952
[4]   Candesartan- and atenolol-based treatments induce different patterns of carotid artery and left ventricular remodeling in hypertension [J].
Ariff, Ben ;
Zambanini, Andrew ;
Vamadeva, Sarita ;
Barratt, Dean ;
Xu, Yun ;
Sever, Peter ;
Stanton, Alice ;
Hughes, Alun ;
Thom, Simon .
STROKE, 2006, 37 (09) :2381-2384
[5]   Improvement in blood pressure, arterial stiffness and wave reflections with a very-low-dose perindopril/indapamide combination in hypertensive patient - A comparison with atenolol [J].
Asmar, RG ;
London, GM ;
O'Rourke, ME ;
Safar, ME .
HYPERTENSION, 2001, 38 (04) :922-926
[6]   Role of Pulse Pressure Amplification in Arterial Hypertension Experts' Opinion and Review of the Data [J].
Avolio, Alberto P. ;
Van Bortel, Luc M. ;
Boutouyrie, Pierre ;
Cockcroft, John R. ;
McEniery, Carmel M. ;
Protogerou, Athanase D. ;
Roman, Mary J. ;
Safar, Michel E. ;
Segers, Patrick ;
Smulyan, Harold .
HYPERTENSION, 2009, 54 (02) :375-383
[7]   Local pulse pressure and regression of arterial wall hypertrophy during long-term antihypertensive treatment [J].
Boutouyrie, P ;
Bussy, C ;
Hayoz, D ;
Hengstler, J ;
Dartois, N ;
Laloux, B ;
Brunner, H ;
Laurent, S .
CIRCULATION, 2000, 101 (22) :2601-2606
[8]   Arterial pressure lowering effect of chronic atenolol therapy in hypertension and vasoconstrictor sympathetic drive [J].
Burns, J ;
Mary, DASG ;
Mackintosh, AF ;
Ball, SG ;
Greenwood, JP .
HYPERTENSION, 2004, 44 (04) :454-458
[9]   Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE):: a randomised trial against atenolol [J].
Dahlöf, B ;
Devereux, RB ;
Kjeldsen, SE ;
Julius, S ;
Beevers, G ;
de Faire, U ;
Fyhrquist, F ;
Ibsen, H ;
Kristiansson, K ;
Lederballe-Pedersen, O ;
Lindholm, LH ;
Nieminen, MS ;
Omvik, P ;
Oparil, S ;
Wedel, H .
LANCET, 2002, 359 (9311) :995-1003
[10]   Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA):: a multicentre randomised controlled trial [J].
Dahlöf, B ;
Sever, PS ;
Poulter, NR ;
Wedel, H ;
Beevers, DG ;
Caulfield, M ;
Collins, R ;
Kjeldsen, SE ;
Kristinsson, A ;
McInnes, GT ;
Mehlsen, J ;
Nieminen, M ;
O'Brien, E ;
Östergren, J .
LANCET, 2005, 366 (9489) :895-906